Career Center

SoMCC Event


  Industry Insights Seminar: RNA Therapeutics -
New Applications of RNA in Research and Drug Development & Related Career Opporunties, Merck Research Laboratories

Date:   Tuesday, January 8, 2008
Time:   12:00 -1:00 PM (Presentation and Q&A)
1:00-1:30 PM (Informal reception)

Location:   Clark Center Auditorum

Sponsor:   School of Medicine Career Center (SoMCC)

Event details:  

The discovery of RNAi has revolutionized studies of gene function, and has proven to be an invaluable tool for studying and manipulating gene expression.  RNAi technology is utilized in both research and drug development, and the strength of synthetic RNA as a therapeutic modality is increasingly recognized.  In brief, the introduction of silencing RNA (siRNA) into animals can decrease the expression of specific proteins via silencing of their messenger RNA.  Sirna Therapeutics harnessed the potential of RNAi by creating potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases.  Sirna, acquired by Merck in December 2006, is at the forefront of the effort to create RNAi- based therapies and leverage the vast potential of this technology to ultimately treat patients.

Merck Research Laboratories has launched a significant internal effort with the goal of providing powerful clinical research tools to Merck investigators and ultimately RNA therapeutics to patients in need of safe and effective therapy.  This seminar provides first-hand insights into new and exciting applications of RNA in research and drug development, along with a view to related career considerations and opportunities, introduced and presented by one of the worlds leading scientist-executives in the field. 


About our Speaker:  
Dr. Alan Sachs, is VP, RNA Therapeutics, Merck Research Laboratories.  A Stanford Medical School alum, Alan was Associate Professor of Molecular and Cell Biology at UC Berkeley, and a Whitehead Institute Fellow at the Whitehead Institute for Biomedical Research in Cambridge, MA.  He is one of the leading figures in the field of mRNA translation and regulation, and has made landmark contributions, particularly to the understanding of the role of the poly(A) tail in translation and mRNA stability.  Prior to his current role, Alan was responsible for scientific and executive leadership at Rosetta Inpharmatics, a wholly owned subsidiary of Merck and Co., Inc.. 

Alan earned his B.A. in Biochemistry at Cornell University, and completed his M.D./Ph.D. (Cell Biology) as part of the MSTP program at Stanford University.

Free and open to Stanford ID holders.
Additional information and/or registration:   RSVP required. Space is limited, register online

Footer Links: